Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib PK in Patients With Advanced HCC and Child-Pugh B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older~* Diagnosis of HCC: diagnosis based on the following criteria:~  1. 1 radiologic technique: Focal lesion \>1 cm with arterial hypervascularization in 4-phase CT or dynamic contrast enhanced MRI OR~ 2. 2 coincidental dynamic radiologic techniques (CT or MRI) in case one imaging technique is non-conclusive and lesion \> 1 cm OR~ 3. biopsy proven HCC~* Patients with advanced HCC - BCLC stage C~* Cancer related symptoms (symptomatic tumors, ECOG Performance status 1-2), macrovascular invasion (either segmental or portal invasion) or extrahepatic spread (lymph node involvement or distant metastases)~* Not eligible for TACE (; i.e. diffuse tumors, tumors larger than 5 cm)~* Not eligible for curative resection or RFA~* Patients with CP-B liver cirrhosis (CP-B score 7 or 8)~* Capable of giving written informed consent~* History of organ transplant (including prior liver transplantation) is allowed~* HIV, congenital immune defect, any immunosuppressive therapy for autoimmune disease (rheumatoid arthritis) is allowed~Exclusion Criteria:~Subjects will not be enrolled in the study if any of the following criteria apply:~* CP-B9 liver cirrhosis~* CP-C liver cirrhosis~* Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial~* Concurrent antitumoral treatment for HCC or other malignancies~* Not eligible for sorafenib treatment~* Bilirubin \> 51 micromol/L~* If female, pregnant or breast feeding (females of child-bearing potential must use adequate contraception and must have a negative pregnancy test performed within 7 days prior to inclusion into this study)~* If male, not using adequate birth control measures~* One or more of the following: - WBC \<2,500 cells/mm3, - ANC \<1,500 cells/mm3, - platelets \<50,000/mm3,~* ECOG performance status \>2~* Patients with known GFR \<30 mL/min/1.73m2~* Significant cardiovascular disease; e.g., myocardial infarction within 6 months of inclusion, chronic heart failure (New York Heart Association class III or IV), unstable coronary artery disease~* Uncontrolled hypertension i.e. systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 90 mm Hg despite optimal medical management (2 classes of antihypertensive drugs)~* History of hemorrhage / bleeding events of grade 3 or worse within 30 days before inclusion into this study~* Previous variceal bleeding within the past 3 months~Additional exclusion criteria for cocktail test~* Consumption of grapefruit or grapefruit juice and/or kumquats, pummelos, exotic citrus fruit (i.e., star fruit, bitter melon) or grapefruit hybrids from seven days prior to the first dose of cocktail.~* Use of herbal medicine or medication that induce or inhibit CYP3A4/5, CYP2C9, CYP2D6, CYP1A2 and CYP2C19~* Use of omeprazole, warfarin, metoprolol, caffeine or midazolam (=medication of the probe cocktail)~* Concurrent anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib with midazolam clearance test (Type: EXPERIMENTAL): Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose).
- Sorafenib with CYP cocktail test (Type: EXPERIMENTAL): In this subgroup of 15 patients (in the Academic Medical Center Amsterdam), the midazolam test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose).

Based on this trial design, predict the completion outcome and termination type (if applicable).